Accurate Characterization of Bladder Cancer Cells with Intraoperative Flow Cytometry

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Nov 11

PMID 36358858

Authors

Athanasios Paliouras

Georgios S Markopoulos

Stavros Tsampalas

Stefania Mantziou

Ioannis Giannakis

Dimitrios Baltogiannis

Georgios K Glantzounis

George A Alexiou

Evangelia Lampri

Nikolaos Sofikitis

George Vartholomatos

Affiliations

Soon will be listed here.

Abstract

Bladder cancer represents a major health issue. Transurethral resection is the first line treatment and an accurate assessment of tumor margins might warrant complete tumor removal. Genomic instability and proliferative potential are common hallmarks of cancer cells. We have previously demonstrated the utility of intraoperative flow cytometry (iFC), a next-generation margin evaluation methodology for assessment of DNA content, in the detection of several types of malignancy. In the current study we investigated the possible value of iFC in the characterization of bladder cancer during surgery. Samples from a population of 52 people with urothelial cancer were included in the study. The total time for iFC evaluation is 3-5 min per sample and included a two-step analysis, including DNA-index and Tumor-index calculation. First, DNA-index calculation revealed 24 hyperploid and one hypoploid tumor. Second, cell cycle analysis and Tumor-index calculation revealed that tumor samples are distinguished from normal cells based on their significantly higher proliferative potential. The standard for iFC evaluation was pathology assessment and revealed that our protocol exhibits an accuracy of 98% in defining the presence of cancer cells in a given sample. Our results support the further assessment of iFC value towards its use as a novel malignancy evaluation tool in transurethral resections.

Citing Articles

Intraoperative Flow Cytometry for the Rapid Diagnosis and Validation of Surgical Clearance of Non-Melanoma Skin Cancer: A Prospective Clinical Feasibility Study.

Markopoulos G, Lampri E, Tragani I, Kourkoumelis N, Vartholomatos G, Seretis K Cancers (Basel). 2024; 16(4).

PMID: 38398076 PMC: 10887295. DOI: 10.3390/cancers16040682.

Critical Assessment of Cancer Characterization and Margin Evaluation Techniques in Brain Malignancies: From Fast Biopsy to Intraoperative Flow Cytometry.

Liaropoulos I, Liaropoulos A, Liaropoulos K Cancers (Basel). 2023; 15(19).

PMID: 37835537 PMC: 10571534. DOI: 10.3390/cancers15194843.

Assessment of Gliomas' Grade of Malignancy and Extent of Resection Using Intraoperative Flow Cytometry.

Vartholomatos G, Markopoulos G, Vartholomatos E, Goussia A, Dova L, Dimitriadis S Cancers (Basel). 2023; 15(9).

PMID: 37173975 PMC: 10177593. DOI: 10.3390/cancers15092509.

Intraoperative Flow Cytometry for the Evaluation of Meningioma Grade.

Alexiou G, Markopoulos G, Vartholomatos E, Goussia A, Dova L, Dimitriadis S Curr Oncol. 2023; 30(1):832-838.

PMID: 36661712 PMC: 9858265. DOI: 10.3390/curroncol30010063.

References

Netto G . Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet. 2016; 387(10031):1881-2. DOI: 10.1016/S0140-6736(16)00654-1. View

Markopoulos G, Harissis H, Andreou M, Alexiou G, Vartholomatos G . Intraoperative flow cytometry for invasive breast cancer conserving surgery: A new alternative or adjunct to cavity shaving technique?. Surg Oncol. 2022; 42:101712. DOI: 10.1016/j.suronc.2022.101712. View

Allard P, Bernard P, Fradet Y, Tetu B . The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol. 1998; 81(5):692-8. DOI: 10.1046/j.1464-410x.1998.00628.x. View

Vartholomatos G, Basiari L, Kastanioudakis I, Psichogios G, Alexiou G . The Role of Intraoperative Flow Cytometry in Surgical Margins of Head and Neck Malignancies. Ear Nose Throat J. 2020; 100(10_suppl):989S-990S. DOI: 10.1177/0145561320931989. View

Bernardo C, Eriksson P, Marzouka N, Liedberg F, Sjodahl G, Hoglund M . Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: An integrated immunohistochemical analysis. Hum Pathol. 2022; 122:11-24. DOI: 10.1016/j.humpath.2022.01.006. View

Vartholomatos G, Alexiou G, Batistatou A, Kyritsis A . Intraoperative cell-cycle analysis to guide brain tumor removal. Proc Natl Acad Sci U S A. 2014; 111(36):E3755. PMC: 4246950. DOI: 10.1073/pnas.1413155111. View

Sanguedolce F, Russo D, Mancini V, Selvaggio O, Calo B, Carrieri G . Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review. Int J Surg Pathol. 2018; 27(2):120-133. DOI: 10.1177/1066896918814198. View

Kamat A, Dinney C, Gee J, Grossman H, Siefker-Radtke A, Tamboli P . Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007; 110(1):62-7. DOI: 10.1002/cncr.22756. View

Emilio S, Luigi V, Riccardo B, Carlo G . Lifestyle in urology: Cancer. Urologia. 2019; 86(3):105-114. DOI: 10.1177/0391560319846012. View

10.

Vartholomatos E, Alexiou G, Markopoulos G, Lazari D, Tsiftsoglou O, Chousidis I . Deglucohellebrin: A Potent Agent for Glioblastoma Treatment. Anticancer Agents Med Chem. 2019; 20(1):103-110. DOI: 10.2174/1871520619666191121110848. View

11.

Doherty S, McKeown S, McKelvey-Martin V, Downes C, Atala A, Yoo J . Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst. 2003; 95(24):1859-68. DOI: 10.1093/jnci/djg120. View

12.

Mitra A, Datar R, Cote R . Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006; 24(35):5552-64. DOI: 10.1200/JCO.2006.08.2073. View

13.

Markopoulos G, Goussia A, Bali C, Messinis T, Alexiou G, Vartholomatos G . Resection Margins Assessment by Intraoperative Flow Cytometry in Pancreatic Cancer. Ann Surg Oncol. 2022; . DOI: 10.1245/s10434-022-11645-7. View

14.

Zhu S, Yu W, Yang X, Wu C, Cheng F . Traditional Classification and Novel Subtyping Systems for Bladder Cancer. Front Oncol. 2020; 10:102. PMC: 7025453. DOI: 10.3389/fonc.2020.00102. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Vartholomatos E, Mantziou S, Alexiou G, Lazari D, Sioka C, Kyritsis A . An NF-κB- and Therapy-Related Regulatory Network in Glioma: A Potential Mechanism of Action for Natural Antiglioma Agents. Biomedicines. 2022; 10(5). PMC: 9138293. DOI: 10.3390/biomedicines10050935. View

17.

Vartholomatos E, Vartholomatos G, Alexiou G, Markopoulos G . The Past, Present and Future of Flow Cytometry in Central Nervous System Malignancies. Methods Protoc. 2021; 4(1). PMC: 7839046. DOI: 10.3390/mps4010011. View

18.

Mitra A, Hansel D, Cote R . Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol. 2012; 39(5):524-33. PMC: 3478886. DOI: 10.1053/j.seminoncol.2012.08.008. View

19.

Georvasili V, Markopoulos G, Batistatou A, Mitsis M, Messinis T, Lianos G . Detection of cancer cells and tumor margins during colorectal cancer surgery by intraoperative flow cytometry. Int J Surg. 2022; 104:106717. DOI: 10.1016/j.ijsu.2022.106717. View

20.

Vartholomatos G, Basiari L, Exarchakos G, Kastanioudakis I, Komnos I, Michali M . Intraoperative flow cytometry for head and neck lesions. Assessment of malignancy and tumour-free resection margins. Oral Oncol. 2019; 99:104344. DOI: 10.1016/j.oraloncology.2019.06.025. View